|1.||Suttle, A Benjamin: 18 articles (02/2015 - 06/2009)|
|2.||Sternberg, Cora N: 15 articles (01/2015 - 02/2008)|
|3.||Hutson, Thomas E: 11 articles (06/2015 - 02/2008)|
|4.||Choueiri, Toni K: 10 articles (03/2015 - 03/2011)|
|5.||Pandite, Lini N: 10 articles (01/2015 - 12/2006)|
|6.||Pandite, Lini: 8 articles (07/2015 - 06/2009)|
|7.||Xu, Chun-Fang: 8 articles (03/2015 - 06/2011)|
|8.||McCann, Lauren: 8 articles (01/2015 - 01/2010)|
|9.||Bible, Keith C: 8 articles (06/2014 - 07/2010)|
|10.||Hackshaw, Michelle D: 7 articles (06/2015 - 08/2013)|
|1.||Renal Cell Carcinoma (Grawitz Tumor)
01/01/2013 - "The Appraisal Committee concluded that pazopanib should be recommended as a first-line treatment option for people with advanced renal cell carcinoma who have not received prior cytokine therapy and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and if the manufacturer provides pazopanib with a 12.5 % discount on the list price and provides a possible future rebate linked to the outcome of the head-to-head COMPARZ trial, as agreed under the terms of the patient access scheme and to be confirmed when the COMPARZ trial data are made available."
01/01/2014 - "Evaluation of the safety and efficacy of pazopanib, a multikinase angiogenesis inhibitor, in a single-arm, open-label, extension study (VEG107769/NCT00387764) for placebo-treated patients with advanced renal cell carcinoma (RCC) from a randomized, double-blind, placebo-controlled phase III study (VEG105192/NCT00334282). "
01/01/2014 - "An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma."
07/01/2014 - "The data confirm other experiences showing the efficacy of pazopanib as first-line therapy in metastatic renal cell carcinoma. "
05/01/2014 - "We report a retrospective monoinstitutional experience of first-line treatment with pazopanib in a series of patients with metastatic renal cell carcinoma. "
|2.||Sarcoma (Soft Tissue Sarcoma)
07/01/2013 - "In this review, we will revisit the efficacy of pazopanib in sarcomas, and present a patient case that illustrates two of many unanswered questions: which sarcoma patients are most likely to benefit from pazopanib therapy, and what criteria are best suited to accurately detect benefit in clinical trials? "
01/01/2013 - "The randomized, double-blind, placebo-controlled, Phase III PALETTE (pazopanib for metastatic soft-tissue sarcoma) study demonstrated improved progression-free survival in patients receiving pazopanib compared with placebo. "
11/12/2012 - "The clinical efficacy of oral pazopanib in patients with metastatic soft tissue sarcoma (STS) was demonstrated in a randomized, double-blind, placebo-controlled, phase III trial (PALETTE), generally confirming the findings of an earlier, noncomparative phase II study. "
01/01/2015 - "Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series."
09/01/2015 - "Health-related quality of life (HRQoL) was an exploratory endpoint in the PALETTE trial, a global, double-blind, randomized, phase 3 trial of pazopanib 800 mg versus placebo as second-line or later treatment for patients with advanced soft tissue sarcoma (N = 369). "
02/20/2010 - "CONCLUSION Pazopanib demonstrated significant improvement in PFS and tumor response compared with placebo in treatment-naive and cytokine-pretreated patients with advanced and/or metastatic RCC."
07/01/2013 - "Pazopanib 800 mg was shown to be an effective treatment for RCC that increased the tumor shrinkage rate by 267 % compared with placebo and reduced the likelihood of developing new lesions."
10/01/2010 - "Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study."
11/01/2015 - "Associations between pazopanib-induced-HTN and antitumour efficacy were retrospectively assessed across 2 prospective studies (European Organisation for Research and Treatment of Cancer (EORTC) study 62043 and 62072) in metastatic STS patients who received pazopanib 800mg daily. "
07/01/2015 - "Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients."
01/01/2015 - "After clinical improvement, the pazopanib was reintroduced at reduced dose; however, a few days later, our patient was admitted for worsening dyspnoea and fatigue. "
01/01/2015 - "Despite a rapid tumour response, fatigue rapidly appeared, requiring treatment interruption 2 weeks after pazopanib introduction. "
08/22/2013 - "The mean change from baseline in 11 of 14 health-related quality-of-life domains, particularly those related to fatigue or soreness in the mouth, throat, hands, or feet, during the first 6 months of treatment favored pazopanib (P<0.05 for all 11 comparisons). "
12/01/2008 - "In phase I and II clinical trials, pazopanib was generally well tolerated with the main side effects being hypertension, fatigue or gastrointestinal disorders. "
08/01/2014 - "Because of an episode of hand-foot syndrome and hepatic impairment, the 800-mg daily dose of pazopanib was reduced to a daily dose of 600 mg, which had to be further reduced to a daily dose of 400 mg owing to fatigue and anorexia. "
|5.||Breast Neoplasms (Breast Cancer)
02/01/2012 - "Several trials of pazopanib monotherapy and combination therapy in breast cancer have been completed or are underway. "
02/01/2012 - "In this article, the clinical development of pazopanib as it relates to breast cancer is reviewed including its evaluation in clinical trials and side effect profile. "
01/01/2012 - "The purpose of this study was to analyze acute locoregional toxicity in patients with breast cancer receiving concurrent pazopanib and RT. "
01/01/2010 - "Pazopanib may be of interest for future studies in breast cancer, including in combination with other systemic agents."
06/01/2013 - "Pazopanib inhibits the activation of PDGFRβ-expressing astrocytes in the brain metastatic microenvironment of breast cancer cells."
|2.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|3.||sorafenib (BAY 43-9006)
|5.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|6.||axitinib (AG 013736)
|1.||Drug Therapy (Chemotherapy)
|5.||Self Administration (Administration, Self)